Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Evolving Foundations

CAR T-Cell Therapy: Updates in Nursing Management

Brittney Baer
CJON 2021, 25(3), 255-258 DOI: 10.1188/21.CJON.255-258

Chimeric antigen receptor (CAR) T-cell therapy is an evolving treatment used for hematologic malignancies; it requires specialized nursing care and knowledge. This article discusses updates in the nursing management of CAR T-cell therapies and their use in adult patients. A comprehensive review of the literature, including peer-reviewed articles and pharmaceutical drug labels, was conducted. Oncology and intensive care unit nurses will need to be knowledgeable about and remain current in the management of patients receiving CAR T-cell therapies because they pose different challenges than seen with traditional chemotherapy regimens.

AT A GLANCE

  • CAR T-cell therapies are on the rise, with nursing playing an integral role in the care of patients receiving them.
  • Nurses should know their facility’s standard operating procedures in the care of patients undergoing CAR T-cell therapy.
  • Patients receiving CAR T-cell therapies require high levels of close monitoring and vigilant nursing care during their treatment course; prompt toxicity intervention is key to improved patient outcomes.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or